the bar’s not set higher for OSL. In drug terms OSL also has...

the bar’s not set higher for OSL. In drug terms OSL also has only phase 1/2 “single arm small study with modest data” but its regulatory approval is more to do with quirk of Ce marking that accepts lower evidence for device, (but would not be enough for FDA).
for drugs, at any one time probably a dozen hungry cash rich Pharma companies scouting for assets to beef up R&D pipelines, early phase positive proof of concept studies (phase 2) often enough for big Pharma to make acquisition especially in boom area like oncology & fancy immunotherapies. So if biotech announces positive data, investors get excited , see dollars signs thinking a Pharma will come along any minute.
Maybe this explains what you’re seeing?
not really the same with devices is it...
drugs pretty easy to give too , anybody can do it not much skill needed. But this is specialised device that needs specialised procedure done by people trained in eus . Which also means any eus supply constraints isn’t good for osl.
perhaps market wants to see evidence of consistent sales that reach some sort of critical mass with Osl? Doubt a few self paying patients will cut it imo.